Apimeds Pharmaceuticals US, Inc. (APUS)
NYSEAMERICAN: APUS · Real-Time Price · USD
1.620
+0.010 (0.62%)
Aug 13, 2025, 4:00 PM - Market closed
Company Description
Apimeds Pharmaceuticals US, Inc. operates as a clinical stage biopharmaceutical company in the United States.
It researches, develops, manufactures, commercializes, and sells Apitox, a purified, pharmaceutical grade venom of the Apis mellifera, or honeybee for the treatment of inflammation and pain management symptoms associated with osteoarthritis and multiple sclerosis.
The company was incorporated in 2020 and is based in Matawan, New Jersey.
Apimeds Pharmaceuticals US, Inc.
| Country | United States |
| Founded | 2020 |
| IPO Date | May 9, 2025 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 2 |
| CEO | Erik Emerson |
Contact Details
Address: 100 Matawan Road, Suite 325 Matawan, New Jersey 07747 United States | |
| Phone | 848 201 5010 |
| Website | apimedsus.com |
Stock Details
| Ticker Symbol | APUS |
| Exchange | NYSEAMERICAN |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $4.00 |
| CIK Code | 0001894525 |
| CUSIP Number | 03771D102 |
| ISIN Number | US03771D1028 |
| Employer ID | 85-1099700 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Erik C. Emerson | Chief Executive Officer and Director |
| Dr. Christopher M. H. Kim M.D. | Chief Medical Officer and Chairman |
| Erick J. Frim | Chief Financial Officer |
| Brian Peters | Head of Proprietary AI Division |
| Dr. Susan M. Kramer Dr. P.H. | Senior Vice President of Clinical Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 16, 2025 | 8-K | Current Report |
| Jun 5, 2025 | 8-K | Current Report |
| May 23, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
| May 20, 2025 | 8-K | Current Report |
| May 20, 2025 | 10-Q | Quarterly Report |
| May 19, 2025 | SCHEDULE 13D | Filing |
| May 15, 2025 | NT 10-Q | Notification of inability to timely file Form 10-Q or 10-QSB |
| May 12, 2025 | 8-K | Current Report |
| May 9, 2025 | 424B4 | Prospectus |
| May 5, 2025 | EFFECT | Notice of Effectiveness |